Evaluation of the Safety and Efficacy of Hyaluronic Acid Injection in Labia Majora Augmentation

Inclusion Criteria: * Gender: female. * Age: more than 18 years old. * Patient affected by labia majora atrophy/hypotrophy as per investigator's judgement and expressing the wish for volume augmentation of the labia majora. * Patient able to understand and sign the informed consent for study enrolment. * Patient having given freely and expressly her informed consent. * Patient affiliated to a health social security system. * Female of childbearing potential should use a contraceptive regimen recognized as effective since at least 12 weeks before inclusion and during all the study. Exclusion Criteria: * Pregnant or breastfeeding woman or planning a pregnancy during the study * Women who gave birth within 4 months before inclusion. * Patient who had been deprived of their freedom by administrative or legal decision or who is under guardianship. * Patient in a social or sanitary establishment. * Patient suspected to be non-compliant according to the investigator's judgment. * Patient suffering from a severe or progressive disease. * Patient with history of auto immune disease. * Patient immunosuppressed. * Patient suffering of haemostatic disorder. * Patient presenting with acute or chronic skin diseases. * Patient is prone to active inflammatory or infectious processes or presenting clinical signs of inflammation in or close to the labia majora. * Patient presenting bacterial, fungal or viral infection in or close to labia majora. * Patient with history of streptococcal disease. * Patient with recurrent genital herpes (several times a year). A patient asymptomatic in the 6 months before inclusion is eligible. * Patient with history of pre-cancerous condition or cancer in areas close to the injection site (external urogenital, anal or vaginal). * Patient with an actual cancer or presence of pre-cancerous cells (vulvar dysplasia). * Patient with a known tendency to develop keloid or hypertrophic scars. * Patient with known allergy or hypersensitivity to hyaluronic acid or to one of Genefill Contour, Desirial® Plus, anesthesia (if applicable) and disinfectant components. * Patient with multiple allergies. * Patient with a condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk. * Patient who started oestrogen therapies for treatment of vulvovaginal symptomatology within 3 months before inclusion. * Patient under treatment for bacterial, fungal or viral infection. * Patient under treatment with aspirin, anticoagulant, platelets aggregation inhibiting drugs, NSAIDs, immunosuppressive therapy and Vitamin C or treated within one week before inclusion. * Patient under local hydrating treatment within four weeks before inclusion. * Patient with history of correction with another resorbable implants with a similar indication within 12 months before inclusion. * Patient with history of correction with permanent implants including fat graft or semi-permanent in the area of injection. * Patient who underwent a surgery on labia minora within 12 months before inclusion. * Patient who underwent a surgery on labia majora at any time. * Patient having intolerance to gram-positive bacteria.